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Background: Previous studies have suggested a role for platelets in the pathogenesis of pulmonary hypertension (PH). Platelet function has not 
been critically evaluated. We hypothesized that platelet function would be differentially altered depending on the etiology of PH.
Methods: Baseline clinical disease subtype characteristics, and B-natriuretic peptide levels were obtained on patients recruited consecutively from 
the Irish National Pulmonary Hypertension Unit. Platelet function was carefully assessed using a modification of light transmission aggregometry. 
Platelet aggregation in response to increasing concentrations of agonists- Arachadonic Acid, Adenosine Diphosphate, Collagen, Epinephrine, and 
Thrombin Receptor Activating Peptide, was assessed. Multiple comparisons between subgroups were made by ANOVA analysis using the Bonferroni 
Correction where appropriate.
Results: A total of 106 patients were recruited. 26 patients had underlying thromboembolic pulmonary hypertension, 27 had inflammatory disease 
related pulmonary hypertension, 23 had idiopathic pulmonary hypertension, and a further 24 had either pulmonary venous hypertension from left 
heart disease, or congenital heart related pulmonary hypertension. Six patients were excluded due to incomplete platelet function assays
No differences existed between the groups in terms of demographics, NYHA class, directed- therapy use, anti-coagulation, right heart pressures, six-
minute walk test or B-naturetic peptide levels.
Platelet aggregation was significantly greater in response to all five agonists in the chronic thromboembolic pulmonary hypertension cohort 
compared to pulmonary hypertension due to other causes, p=0.001.
Moreover this increase in platelet reactivity was not attributable to differences in gender, treatment subtypes, and whether or not surgical pulmonary 
thrombo-endarterectomy had been performed.
Conclusion: Patients with thromboembolic PH have increased platelet aggregation to a range of agonists. This pro-thrombotic bias may contribute 
to disease progression. Our results suggest that there may be a therapeutic role for antiplatelet agents in patients with thromboembolic PH
